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Abstract
Bovine viral diarrhea virus (BVDV) replicons with deletions within the capsid, ERNS or E1 encoding region were constructed and efficiently
packaged with a helper cell line. High titres of packaged replicons were observed as early as 24 h after transfection, whereas no virus progeny could
be detected after transfection of non-complementing cells. Infection of bovine cell cultures with rescued viruses resulted in one cycle of replication
without release of infectious virus particles, and no genetic reversion of the generated viruses was detected. Packaged replicons with a deletion
within the capsid-coding region were characterized in vivo in immunization and challenge trials. Following immunization of calves with the
replication-deficient virus, neither virus shedding nor viremia was detected. After challenge infection with virulent BVDV, all vaccinates were
completely protected from disease as measured by the absence of viremia and shedding of challenge virus, which indicated that a ‘sterilizing
immunity’ could be induced with the generated replication-deficient packaged replicons.
© 2007 Elsevier Inc. All rights reserved.Keywords: Bovine viral diarrhea virus; Pestivirus; Trans-complementation; Replicon; VaccineIntroduction
The family Flaviviridae contains a number of important
human and animal pathogens which are classified into three
closely related genera: Flavivirus within which for example
tick-borne encephalitis virus (TBEV), West Nile virus (WNV),
yellow fever virus (YFV) and kunjin virus (KUN) are grouped,
Hepacivirus represented by hepatitis C virus (HCV), and finally
Pestivirus, which represents four different species: bovine viral
diarrhea virus type 1 and 2 (BVDV-1, BVDV-2), classical swine
fever virus (CSFV) and border disease virus (BDV) (Fauquet et
al., 2005). HCV is responsible for severe chronic liver disease in
humans (Overby et al., 1989), but no efficacious vaccine against
the infection has become available.⁎ Corresponding author. Fax: +49 38351 7 151.
E-mail address: martin.beer@fli.bund.de (M. Beer).
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doi:10.1016/j.virol.2007.05.006Pestiviruses can be divided into two different biotypes, cy-
topathogenic (cp) and non-cytopathogenic (ncp) viruses, res-
pectively. BVDV is the causative agent of bovine viral diarrhea,
an economically important disease worldwide (Brownlie et al.,
1984; Houe, 1995). The major disease manifestations of BVDV
infections are located to the genital and reproductive organs and
infections result in reduced fertility, abortions and the generation
of persistently infected calves, which can develop fatal “Mucosal
Disease” (Baker, 1995; Bolin, 1995a; Moennig and Liess, 1995).
The pestivirus genome is a single-stranded RNA of positive
orientationwith a length of approximately 12.3 kb. It contains one
large open reading frame (ORF), which is flanked by non-
translated regions (NTR) at both genome termini. The large ORF
is translated into one polyprotein, which is co- and post-
translationally processed into 12 mature proteins by viral and
cellular proteases (Collett et al., 1988; Thiel et al., 1991;
Rümenapf et al., 1993). In cp BVDV, nonstructural protein NS3
is more abundantly expressed due to variable insertions allowing
a more efficient cleavage of nonstructural proteins NS2 and NS3
(Collett et al., 1989; Lackner et al., 2004, 2005). Pestivirus
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and three glycosylated envelope proteins (ERNS, E1, and E2). In
natural infection, BVDVantibodies are directed against ERNS, E2
and NS3, but neutralizing activity was predominantly demons-
trated for E2-specific antibodies (Donis, 1995; Potgieter, 1995).
Pestivirus genomes with deletions were first described as
naturally occurring, defective interfering particles (DIs) for
BVDVand CSFV (Kupfermann et al., 1996; Meyers and Thiel,
1995). Many reports relating to the replication of pestiviruses
have been published since the discovery of DIs, the construction
of a host of mutants now considerably facilitated by reverse
genetics systems (Donis, 1995; Kupfermann et al., 1996;
Meyers et al., 1996, 2002; Moormann et al., 1996; Rüggli et al.,
1996; Tratschin et al., 1998; Kümmerer and Meyers, 2000). The
development of autonomously replicating RNAs (replicons)
was the first step towards establishing a cell culture-based
replication system for HCV (Lindenbach et al., 2005; Lohmann
et al., 1999), and chimeric HCV, which could be passaged
efficiently in cultured cells, have recently been reported
(Lindenbach et al., 2005). The number of cell types permissive
for HCV replication is limited, however, and no packaging
system has been reported. In contrast, replicons derived from
other flaviviruses have been shown to be packaged with the help
of complementing cell lines (reviewed in Mandl, 2004; Pijlman
et al., 2006a; Schlesinger and Dubensky, 1999), as was shown
for YFV (Lindenbach and Rice, 1997), KUN (Harvey et al.,
2004; Khromykh et al., 1998, 1999; Liu et al., 2002; Pijlman
et al., 2006b), WNV (Scholle et al., 2004) or TBEV (Gehrke et
al., 2003, 2005). In the case of CSFV, trans-complemented
defective virions that contained either ERNS or E2 deleted
replicons were shown to potentially serve as vaccine candidates
(Maurer et al., 2005; van Gennip et al., 2002; Widjojoatmodjo
et al., 2000). These replicons were trans-complemented using
cell lines constitutively expressing the structural proteins
previously deleted in the replicon genomes. In animal
experiments, pigs were partially protected against lethal
CSFV challenge after immunization with the complemented
virions, and the reported efficacy of packaged CSFV replicons
was dependent on the used deletion mutant as well as the way of
application, with the best results obtained after intradermal
administration (van Gennip et al., 2002).
Only few experiments on trans-complementation of BVDV
replicons have been reported. Defects in the coding region for
nonstructural proteins NS3, NS4a, NS4B and NS5B were found
to be lethal and could not be complemented in trans, whereas
genomic defects in NS5A could be complemented (Grassmann
et al., 2001). Chimeric BVDV in which genes encoding capsid,
ERNS, E1 and E2 were replaced by its HCV counterparts, could
be packaged into virions containing the BVDV structural
proteins provided by a helper virus (Nam et al., 2001). Trans-
complementation of BVDV E2 and p7 has also been described
(Harada et al., 2000), and Reimann et al. (2003) demonstrated
that autonomously replicating E2 deletion mutants were effi-
ciently trans-complemented using a helper cell line (PT_805)
providing all structural BVDV proteins.
Here we describe the construction and trans-complementa-
tion of BVDV genomes with deletions in the C, ERNS or E1encoding region, respectively. All BVDV deletion mutants re-
plicated autonomously, but failed to generate infectious virus
progeny in non-complementing cells. Nevertheless, the differ-
ent deletion mutants could be efficiently packaged using a
helper cell line, and packaged replicons devoid of capsid
(‘pseudovirions’) were shown to induce a sterile immunity.
Novel BVDV replicons are therefore considered highly effica-
cious and safe vaccine candidates.
Results
Construction and characterization of BVDV replicons
We constructed a set of BVDV replicons based on a full-
length infectious cDNA clone of non-cytopathogenic BVDV
strain NCP7 (pA/BVDV/INS−; Meyers et al., 1996). Partial
deletions were introduced in regions coding for a single
structural protein: capsid (NCP7ΔC), ERNS (NCP7Δ ERNS) or
E1 (NCP7Δ E1) (Fig. 1). The different replicons contained
deletions of amino acids 201 to 242 (NCP7ΔC), 321 to 475
(NCP7ΔERNS), or 498 to 654 (NCP7ΔE1).
RNA transcribed from the plasmids encoding NCP7ΔC,
NCP7ΔERNS or NCP7ΔE1 all efficiently replicated in bovine
cell culture post transfection (p.t.). Expression of NS2/3 could
be detected at 24 h p.t. by IF staining for all newly synthesized
replicon RNAs. The intensity of NS2/3-specific immunostain-
ing of NCP7ΔC-, NCP7ΔERNS- or NCP7ΔE1-transfected PT
cells was comparable to cells transfected with full-length NCP7
RNA, and more than 85% of the cells were IF-positive (Table
1). No RNA replication could be detected after transfection of
replication-defective NCP7Δ3′AatII RNA (Reimann et al.,
2003), which was used as a negative control. Transfection of
full-length NCP7 RNA into non-complementing PT cells re-
sulted in virus titers of up to 103 IU/ml at 24 h p.t. In contrast, no
infectious recombinant BVDV could be recovered after trans-
fection of the deletion mutants, and all inoculated KOP-R cell
cultures, which are highly susceptible to BVDV infection (Rei-
mann et al., 2004), remained negative even after serial passages
and co-passages. However, after reinsertion of the genes coding
for C, ERNS or E1 into the respective mutant replicons, growth
of each of the constructed revertant viruses was indistinguish-
able from original BVDV NCP7 (data not shown).
Recovery and characterization of recombinant BVDV
complemented in trans
In order to generate trans-complemented virus, in vitro-
transcribed RNA of the NCP7ΔC, NCP7ΔERNS, NCP7ΔE1,
NCP7Δ3′AatII or full-length NCP7 was transfected into the
complementing helper cell line PT_805 that constitutively
expresses BVDV structural proteins (Reimann et al., 2003). At
24 h p.t., monolayers of PT_805 cells were examined for NS2/3
expression and culture supernatants were passaged and titrated
using KOP-R cells. For all replicons and full-length clone
NCP7, NS2/3 staining following RNA transfection led to
immunofluorescence patterns similar to that obtained with
parental, non-complementing PT cells. Between 50% and 95%
Fig. 1. Schematic diagram of constructs generated in this study and compared to parental full-length BVDVNCP7. Filled boxes represent the BVDV structural protein
region. Horizontal dotted lines show the deleted regions and numbers indicate the nucleotide (nt) or amino acid (aa) position in the BVDV full-length RNA. Lines at
the left and the right ends indicate untranslated regions. Npro, autoprotease; C, capsid protein; ERNS, E1, E2, envelope proteins; p7, nonstructural protein; NS2 to NS5,
nonstuctural proteins; 3′NTR and 5′NTR, non-coding regions. The scale in kb is given.
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(data not shown). Infectious, recombinant BVDV was detected,
however, only in supernatants from PT_805 cells transfected
with NCP7ΔC, NCP7ΔERNS, NCP7ΔE1 or NCP7 RNA (Table
1). Inoculation of KOP-R cells with the packaged replicons (so-
called ‘pseudovirions’) present in the PT_805 supernatants
resulted in positive IF staining, and it was evident that only
single cells or two adjacent cells, likely in the process of cell
division, were expressing BVDV proteins (Figs. 2A and B). In
addition, the pseudovirions were not able to spread from cell to
cell to form foci typical for replicating and spreading BVDV
(Fig. 2B). Virus titers of the complemented viruses NCP7ΔC_
trans, NCP7ΔE1_trans and NCP7ΔERNS_trans varied between
105.5 and 106.125 IU/ml at 24 h p.t. (Table 1). After transfection
of full-length NCP7 RNA into complementing PT_805 cells,Table 1
Replication and trans-complementation of BVDV replicons
Construct Replication a after RNA
transfection in PT cells (24 h)
1st passage b (24 h, 48 h,
72 h) on KOP-R-cells
NCP7 ++ (P) e + (103 IU/ml)
NCP7ΔC ++ f ∅f
NCP7ΔERNS ++ ∅
NCP7ΔE1 ++ ∅
NCP7ΔAatII ∅ ∅
a PT cells were transfected with in vitro-transcribed RNA and IF-stained for NS3-
b KOP-R cells were inoculated with undiluted supernatants 24 h, 48 h and 72 h after
specific Mabs 5 days post inoculation.
c PT_805 cells were transfected with in vitro-transcribed RNA and the supernatan
three independent experiments is shown as infectious units (IU; Reimann et al., 200
d KOP-R cells were inoculated using supernatants of transfected PT_805 cells wi
inoculation experiments are shown.
e P indicates the detection of virus plaques after NS3-staining (N10 cells).
f ∅=no BVDV NS3-specific IF-signal; +=weak positive NS3-IF-signal and b50
g nd=not done.virus titers of 107.3 IU/ml could be detected at that time point. In
contrast, no complemented BVDV could be detected after
passaging of PT_805 cell-culture supernatants transfected with
replication defective NCP7Δ3′AatII (Table 1). Furthermore,
PT_805 cells were more efficient in packaging of the replicons
than alternative helper systems, like another cell line (PT_875)
expressing only BVDV capsid and ERNS or Sindbis virus re-
plicon-expressed proteins (data not shown).
Cell cultures inoculated with the different types of pseu-
dovirions were stained with E2-, NS3- and ERNS-specific mo-
noclonal antibodies. Cells infected with NCP7-, NCP7ΔC_
trans or NCP7ΔE1_trans could specifically be stained using the
whole set of Mabs at our disposition, while cells infected with
NCP7ΔERNS_trans, as expected, remained negative after stain-
ing with BVDVERNS-specific antibodies (Fig. 2A). The identityTiter of progeny virus c 24 h after transfection
of complementing PT_805 cells (IU/ml)
4th passage d of virus
progeny on KOP-R cells
107.3 (P) + (P)
106.125 ∅
106.00 ∅
105.50 ∅
b100 nd g
expression after 24 h.
transfection of PTcells (1 ml per 105 cells). KOP-R cells were stained with NS3-
ts were titrated after 24 h using KOP-R-cells. The maximum titer of more than
3).
th a titer N105 IU/ml (1 ml per 105 cells). The results of more than 10 different
% IF-positive cells, ++=positive NS3-IF-signal and N50% IF-positive cells.
Fig. 2. (A) IF analysis of KOP-R cell cultures inoculated with trans-complemented replicons. Inoculated cells were analysed 24 h p.i. by IF using NS3-, ERNS-, or E2-
specific monoclonal antibodies (C16, WB210, CA3). Infectious virus could be detected in supernatants of PT_805 cells transfected with all of the engineered replicon
RNAs or RNA of the full-length NCP7 (a–l), but not from cells infected with replication-deficient NCP7Δ3′AatII (m–o). Expression of ERNS could not be detected in
cells inoculatedwith supernatants from packagedNCP7ΔERNS replicons (g). (B) Serial passage of packagedNCP7ΔC replicons on non-complementing bovine KOP-R
cells. Transfected (TF) cells as well as cells infected with supernatants of the various passages were detected by immunofluorescent staining for BVDV non-structural
protein NS3 using monoclonal antibody C16. Only single infected cells were detectable after the 2nd passage, and, following the 4th serial passage, all cells were
negative for NS3 expression.
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encoding regions were additionally analysed by RT–PCR using
RNA extracted from bovine cells infected with the packaged
replicons. Two primer pairs matching the capsid, ERNS or E1
sequences of NCP7 or the heterologous sequence of the
complementing cell line PT_805 were also used to exclude
recombinations or reversions of the deleted genomes. Using
highly sensitive RT–PCR analyses we could confirm not only
the identity of all preparations of packaged replicons but also
the absence of revertants or pseudo-revertants in all prepara-
tions of pseudovirions (data not shown). Consecutive passages
using non-complementing cells also demonstrated that the
packaged replicons were capable of replicating in bovine cells
without generating infectious virus progeny, as is exemplarilyshown for 4 consecutive passages of NCP7ΔC_trans in KOP-R
cells (Fig. 2B).
Immunization and challenge infection of cattle with
NCP7ΔC_trans pseudovirions
After immunization of calves with NCP7ΔC_trans pseudo-
virions, the general condition of the animals remained unal-
tered, irrespective of the immunization route, and neither clin-
ical signs nor shedding of pseudovirions, viremia, or leukopenia
were observed. In addition, virus isolation from blood leuko-
cytes after immunization was negative for all animals (data not
shown). Immunized animals in all groups developed NS3-spe-
cific antibodies following the first immunization with inhibition
Fig. 3. Serological responses (NS3-specific antibodies as well as neutralizing antibody titers) after immunization and challenge infection are shown as means and
standard deviations (error bars) for the individual groups.
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the second immunization (Fig. 3). The neutralizing antibody
titers against the homologous BVDV strain NCP7 (Fig. 3) and
the heterologous BVDV challenge strain SE5508 (data not
shown) ranged from 1:16 to 1:32 after the first immunization,
which increased to values of greater than 1:256 after booster
vaccination. No marked differences between the immunization
routes (“i.m.” or “i.m. and i.n.”) were detectable (Fig. 3). All
control animals (n=10) developed high levels of NS3-specific
and neutralizing antibody titers following challenge. A marked
booster reaction of NS3-specific and neutralizing antibodies
could be detected in particular in animals receiving only one
i.m. dose of pseudovirions (“1x_im” group; Fig. 3).
After challenge infection with heterologous BVDV strain
SE5508, all animals vaccinated twice remained healthy and did
not exhibit any clinical sign of BVDV infection (data not
shown). No leukopenia was observed for animals of the immu-Fig. 4. Relative leukopenia (mean value before challenge infection=100%) in
the different treatment groups is shown as mean percentages. All control animals
as well as the calves immunized once showed a marked leukopenia after chal-
lenge infection. In contrast, all calves immunized twice with packaged NCP7ΔC
replicons were fully protected from BVDV-induced leukopenia.nization groups “2x_im” and “2x_im_in” (Fig. 4). In addition,
neither challenge virus shedding nor viremia could be detected
in these animals (Fig. 5). In contrast, unvaccinated control ani-
mals developed clinical signs such as coughing and fever. Leu-
kopenia, viremia and shedding of the challenge virus until day
10 post challenge infection were also detected (Figs. 4 and 5).
Animals challenged 29 days after the first immunization (group
“1x_im”) were only partially protected, but virus shedding as
well as leukopenia were reduced when compared to sham-
vaccinated control animals (Figs. 4 and 5).
Discussion
In this study, BVDV mutants unable to express functional
structural proteins were constructed (NCP7ΔC, NCP7ΔERNS,
NCP7ΔE1) and characterized. Transfection of in vitro-tran-
scribed RNA of all constructs resulted in efficient replication of
RNA that was comparable to that of parental NCP7 RNA, and
expression of BVDV proteins was readily detected. However, no
infectious virus could be recovered after transfection of cells
permissive for BVDV replication, even after serial passages
using for example the highly susceptible KOP-R cell line. In
contrast, transfection of full-length NCP7 RNA led to pro-
duction of infectious progeny virus and titers of approximately
103 IU/ml were reached at 24 h p.t. These results are in
accordance with earlier studies using NCP7ΔE2 replicons in
which no infectious virus was produced upon transfection of
non-complementing cells (Harada et al., 2000; Reimann et al.,
2003). Naturally occurring subgenomic pestivirus RNAs with
deletions within the genome regions encoding the structural
proteins and non-structural proteins Npro, p7 and NS2 have been
described for BVDV and CSFV isolates (Kupfermann et al.,
1996; Meyers and Thiel, 1995). These so-called defective
interfering particles (DIs) are able to replicate autonomously in
susceptible cells but fail to produce infectious virions (Behrens
et al., 1998; Moser et al., 1996). It is also known that neither the
non-structural proteins Npro, p7 andNS2 nor any of the structural
proteins are essential for RNA replication of pestiviruses
Fig. 5. Viremia and virus shedding after challenge infection. Peripheral blood leukocytes and nasal swabs were inoculated in duplicate into highly susceptible KOP-R
cell cultures and stained for BVDV antigen after 4 to 5 days. Results were scored according to the number of positive inoculations (2=both inoculations BVDV-
positive, 1=1 of 2 inoculations BVDV-positive, 0=no BVDV isolation).
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but infectious virus could be generated by complementing the
missing proteins and packaging the defective genomes with a
helper virus (Kupfermann et al., 1996). Concerning the four
structural proteins of BVDV, E2-deleted replicons have been
reported so far (Harada et al., 2000; Reimann et al., 2003), and it
was demonstrated that E2 is essential for production and release
of infectious virus progeny. Therefore, our experiments also
prove that all structural proteins of BVDV are essential for the
generation of infectious virus.
Trans-complementation of flavivirus proteins has been re-
ported for example in the case of YFVand KUN non-structural
proteins NS1, NS3 and NS5 (Khromykh et al., 1998; Linden-
bach and Rice, 1997), for CSFV-ERNS and -E2 (Frey et al.,
2006; Widjojoatmodjo et al., 2000), and BVDV-E2 and -E2-p7
(Harada et al., 2000; Reimann et al., 2003) using helper cell
lines or viral vectors expressing the deleted proteins. In the
present study, the newly generated replicons NCP7ΔC, NCP
7ΔERNS and NCP7ΔC were efficiently trans-complemented
and packaged into virions using the helper cell line PT_805. It is
important to emphasize that we did not observe any recom-
bination or reversion during numerous trans-complementation
experiments and passages on the PT_805 cells, likely because
we were utilizing a synthetic, codon-optimized version of the
BVDV structural gene region (Reimann et al., 2003), which
greatly reduces the potential for homologous recombination
events. In addition, the PT_805 cells were the most efficientpackaging system available. Nevertheless, novel techniques for
the generation of helper cell lines, like VEEV-replicons (Mason
et al., 2006) will be also tested in the future for the complemen-
tation of BVDV-replicons.
In the first passage, maximum virus titers of the trans-com-
plemented pseudovirions ‘NCP7ΔC_trans’, ‘NCP7ΔE1_trans’
and ‘NCP7ΔERNS_trans’ ranged between 105.5 to 106.125 IU/ml
at 24 h p.t. Infection of non-complementing cells with the
pseudovirions resulted in efficient RNA replication and protein
expression without the generation of infectious virus particles.
After passaging on non-complementing KOP-R cells, no re-
combination or reversion resulting in infectious virions could be
detected either, similar to the situation in PT_805 cells. In-
terestingly, a markedly reduced susceptibility of PT_805 cells to
infection with all trans-complemented replicons engineered
here was observed (data not shown), which is in good agreement
with our earlier findings using NCP7ΔE2_trans pseudovirions
(Reimann et al., 2003). This phenomenon of viral interference
was also described for other pestiviruses (Harada et al., 2000;
Mittelholzer et al., 1997), but, nonetheless, is not well under-
stood. Recent studies of Lee et al. (2005) suggest a dual
mechanism of pestivirus interference, one at the level of viral
entry caused by glycoprotein E2 and a second at the level of viral
RNA replication where the viral and cellular components remain
to be identified. Therefore, the newly constructed replicons as
well as the helper cell line PT_805 will provide a useful basis for
further studies on pestivirus interference. In addition, the direct
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replicon construct in non-complementing cells, as demon-
strated for TBEV (Mandl, 2004), can be investigated in the
future. However, in a first preliminary electron microscopy
analysis, no BVDV-VLPs were detected (data not shown).
The generated BVDV pseudovirions were also characterized
in vivo as a novel approach to control BVDV infections by
vaccination. In spite of the wide use of vaccination against
BVDV infections in comprehensive control programs, serious
concerns exist regarding the safety and/or efficacy of conven-
tional modified live virus or inactivated vaccines (Becher et al.,
2001; Bolin and Ridpath, 1995b; Fernelius et al., 1971; Howard
et al., 1994; Thierauf, 1993). While some of the modified live
virus vaccines were shown to induce a robust immunity similar
to that induced by natural BVDV infection, inactivated BVDV
vaccines are not universally accepted to be sufficiently
efficacious (Beer et al., 2000; Beer and Wolf, 2003; Bolin and
Ridpath, 1995b). Because of the serious risks of an application of
infectious BVDV to pregnant animals, the development of new
efficacious and safe vaccines is of paramount importance. The
main aim of an immunization against BVDV infection is
protection against virus shedding, viremia, and subsequent
transplacental infection of a fetus. In this context, cellular
immunity might play a crucial role for a protective BVDV
immunity (Beer et al., 1997; Collen and Morrison, 2000), which
could also explain the problems of inactivated vaccines to fully
protect against BVDV viremia.
So-called defective in second cycle (DISC) viruses could be
the basis for such an improved BVD/MD vaccine, and pes-
tivirus pseudovirions, such as the various mutant replicons
described here, might be a very promising prototype of a safe
‘live’ vaccine. In experiments using ERNS- or E2-deleted CSFV
replicons, however, only partial protection against subsequent
challenge infection could be demonstrated, and protection was
shown to be restricted to intradermal immunization (van Gennip
et al., 2000; van Gennip et al., 2002).
In our in vivo studies, we concentrated on the capsid-deleted
replicon for the immunization of cattle since the most immu-
nogenic envelope proteins, ERNS and E2, are still expressed by
this construct. In both immunization and challenge trials with
pseudovirions lacking capsid sequences, specific antibody res-
ponses could be detected even after a single intramuscular
immunization. Besides neutralizing antibodies, NS3-specific
antibodies were detected, which are sensitive indicators of
pestiviral RNA replication and protein expression, and both
types of antibodies were efficiently boostered after a second
immunization. In addition, two i.m. applications were as
efficient as two combined ‘i.m.+ i.n.’ applications. It became
clear, however, that only animals immunized twice (i.m. or
i.m.+ i.n.) were completely protected against heterologous
BVDV challenge infection, whereas the one-dose immuniza-
tion reduced clinical signs and virus shedding, but was unable
to induce sterile immunity. Most notably, the observed immune
response against NCP7ΔC pseudovirions was reminiscent of
both inactivated pestivirus vaccines as reflected by low titers
after the first immunization, partial protection against viremia
and effective booster vaccination (Beer and Wolf, 2003), andattenuated live vaccines that are characterized by an early NS3-
specific antibody response and a sterile immunity (Beer and
Wolf, 2003; Moennig et al., 2005). Therefore, the BVDV
standard challenge model with a BVDV type 1 strain not only
simulates a field infection but also allows a clear graduation
between the groups, even without inducing severe clinical
signs. As a further consequence of the results of the immuni-
zation study, additional vaccination and booster schemes are
conceivable, e.g. using inactivated vaccines or recombinant
vectors for booster immunizations.
As an important safety feature and in contrast to packaged
alphavirus replicons (Bredenbeek et al., 1993; Frolov et al.,
1996; Weiss and Schlesinger, 1991), no revertant, pseudo-
revertant or recombined BVDV replicons were detected in our
study. As briefly explained earlier, we suggest that RNA re-
combination is extremely rare or even impossible in the reported
BVDV replicon packaging system that uses a synthetic open
reading frame encoding all structural proteins (Reimann et al.,
2003). While recombination in the non-structural region with a
single template switch was demonstrated for pestiviruses
(Becher et al., 2001), the double template switch needed for a
recombination event in the system presented here has not been
reported and is considered highly unlikely.
In conclusion, we describe here the construction and success-
ful testing of a new pestivirus vaccine prototype, which com-
bines the safety aspects of inactivated vaccines with the efficacy
of an attenuated, modified live vaccine. In contrast to other
flavivirus pseudovirion models, protective immunity could be
induced in a natural virus–host system using intramuscular im-
munization. Furthermore, the reported type of vaccine virus
could also serve as a model for similar capsid-deleted replicons
for related viruses, such as HCV. Since efficiently replicating
systems for HCV are now available (Lindenbach et al., 2005),
our data suggest that the construction and testing of HCV pseu-
dovirions for immunization might be a goal that is worthwhile
pursuing.
Material and methods
Cells and viruses
PT cells (RIE11, CCLV), a permanent ovine cell line, KOP-R
cells (Rie244, CCLV), a diploid bovine esophageal cell line, and
PT_805 cells (Reimann et al., 2003), a cell line expressing the
structural proteins C, ERNS, E1 and E2 of BVDV, were obtained
from the collection of cell lines in veterinary medicine at the
Federal Research Institute for Animal Health, Insel Riems
(CCLV).Cells were grown inDulbecco'sModified EagleMedium
(DMEM) supplemented with 10% BVDV-free fetal bovine serum
(FBS). BVDV strain NCP7 was rescued from infectious cDNA
clone pA/BVDV/Ins− (Meyers et al., 1996) after transfection of PT
cells and passaging in KOP-R cells. Virulent BVDV type 1
challenge virus strain SE5508 (Wolfmeyer et al., 1997) was
propagated in KOP-R cells. Trans-complemented viruses
NCP7ΔC_trans, NCP7ΔE1_trans, and NCP7ΔERNS_trans are
pseudovirions produced after transfection of the different repli-
cons into the helper cell line PT_805.
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assay
For the detection of BVDV proteins, monoclonal antibodies
(Mab) WB210 (anti-ERNS, CVL, Weybridge), CA3 (anti-E2,
TiHo, Hannover, Germany), and C16 (anti-NS3, TiHo, Hann-
over, Germany) were used (Edwards et al., 1988, 1991; Peters et
al., 1986). Standard immunofluorescence (IF) analysis using a
fluorescence-activated cell sorter (FACS, Becton Dickinson) or
a fluorescence microscope (Olympus) were performed as pre-
viously described (Beer et al., 1997; Grummer et al., 2001). For
IF analysis using a fluorescence microscope, cell cultures were
fixed with 3% paraformaldehyde (PFA) and permeabilized
using 0.01% digitonin or fixed/permeabilized using 80% ace-
tone (for E2 staining). After washing with phosphate-buffered
saline (PBS), cells were incubated with the working dilution of
the appropriate Mab for 15 min. After two additional washing
steps with PBS, cells were incubated with an Alexa488 conju-
gate (Invitrogen) for 15 min, finally washed and analyzed by
fluorescence microscopy.
Standard neutralizing assays using inactivated sera were
performed as described previously (Beer et al., 1997; Reimann
et al., 2004). In addition, serum or plasma samples were tested
for the presence of antibodies against BVDV with the com-
mercial ELISA assays HerdCheck BVDVAB (IDEXX), BVD
Virus III Chekit® (Bommeli Diagnostics) and Ceditest® BVDV
(Cedi Diagnostics B.V.) according to the manufacturers'
instructions.
In vitro-transcription and electroporation
In vitro-transcription of linearized, full-length cDNA con-
structs and replicons was performed by T7 RiboMax™ Large
Scale RNA Production System (Promega) according to the
manufacturer's instructions. The amount of RNAwas estimated
by ethidium bromide staining after agarose gel electrophoresis.
For transfections, 1×107 PT_805 or KOP-R cells were de-
tached using a trypsin solution, washed with PBS, mixed with 1
to 5 μg of RNA synthesized in vitro, and electroporated using
an EasyjecT Plus (EquiBio) transfection unit (two pulses at
850 V, 25 μF, 156 Ω).
Polymerase chain reaction (PCR) and sequencing
For PCR, a PTC-200 thermal cycler (MJ Research, Inc.) was
used. DNA based amplification was done using the Expand
High Fidelity PCR System (Roche Molecular Biochemicals).
For RT–PCR, total RNA of virus-infected cells was extracted
using the TRIZOL reagent (Gibco-Life Technologies). RT–
PCR was performed by using the One-step RT–PCR Kit (Qia-
gen), and PCR products were directly sequenced.
Sequencing was carried out using a Thermo Sequenase
Cycle Sequencing Kit (Amersham Biosciences). Nucleotide
sequences were read with a LI-COR automatic sequencer
(MWG Biotech) and analyzed using GCG version 11.1 (Accel-
rys Inc., San Diego, CA). Primers used for PCR or sequencing
were custom synthesized (MWG-Biotech).Plasmid constructs
Mutant BVDV clones are depicted in Fig. 1. They were
constructed based on a full-length cDNA clone, pA/BVDV/
Ins−, harboring the non-cytopathogenic BVDV strain NCP7
genome (Meyers et al., 1996). The specified nucleotide posi-
tions correspond to the BVDV NCP7 genome (Accession No.
BVU43679; Meyers et al., 1996). Restriction enzyme digestion
and cloning procedures were performed according to standard
protocols. PCR fragments used for the construction of the
various replicons were derived from a NCP7 DNA fragment
with a mutated KpnI site at position 2447, which was
subcloned into plasmid pUC18 (Clontech). We constructed
several BVDV NCP7 mutants with in-frame deletions of C,
ERNS, or E1. Sequences known to be important for correct
translocation of viral proteins or for signalase recognition
(Rümenapf et al., 1991) were preserved. The capsid-deleted
replicon NCP7ΔC contained a deletion of amino acids 201–
242 compared to the parental NCP7 ORF. The N-terminal 32
amino acids and the 27 C-terminal amino acids of the C
protein, which are essential for signalase recognition, translo-
cation of the envelope proteins into the endoplasmatic
reticulum (ER), and further processing of the ERNSE1E2
polyprotein (Rümenapf et al., 1991, 1993), were retained. The
construct NCP7ΔERNS was designed with a restricted deletion
within the central region of ERNS (amino acids 321 to 475),
because the N- and C-terminal ERNS sequences also contain
important signal sequences for cellular proteases (Donis et al.,
1988; Rümenapf et al., 1991; Thiel et al., 1991). The envelope
protein E1, which corresponds to amino acids 497 to 692,
harbors two hydrophobic stretches at the C-terminus, which
act as a stop-transfer signal and a signal sequence to induce the
translocation of the envelope protein E2 into the ER lumen.
The hydrophobic sequences also form an anchor for E1.
Therefore, only the N-terminal sequence region was deleted
(amino acids 498 to 654) and 37 C-terminal amino acids were
maintained in the E1-deleted replicon.
Complementation experiments
PT_805 helper cells were transfected with in vitro-tran-
scribed BVDV replicon RNA by electroporation as described
before (Reimann et al., 2003). Cell culture supernatants were
collected 24 h to 48 h post transfection (p.t.), clarified by
centrifugation (10,000×g, 5 min), and titrated using KOP-R
cells. At the day of collection, replication of BVDV was moni-
tored by IF staining.
Pseudovirion titers were determined as infectious units (IU)
as described previously (Reimann et al., 2003). Cell culture
supernatants were titrated in triplicate in log10 steps and 1 ml
was inoculated onto KOP-R cells seeded in 24-well plates. After
12 to 24 h of incubation at 37 °C, cells were washed, detached
with a trypsin solution, and counted. An aliquot of the cells was
stained by IF using a BVDV NS3-specific Mab and analyzed by
flow cytometry. All transfection and passaging experiments
were repeated at least 10 times for each of the three replicon
constructs (Table 1).
385I. Reimann et al. / Virology 366 (2007) 377–386Animal experiments
Four- to six-month-old, healthy, BVD antibody- and virus-
free calves (Simmental breed) were immunized with packaged
NCP7ΔC replicons using different protocols. In two indepen-
dent experiments, three different immunization groups of 5
calves each were investigated: The first group (1x_im) was
immunized once by the intramuscular (i.m.) route at day 0. The
second group (2x_im) received two i.m. immunizations at days
0 and 29, and the third group (2x_im_in) was immunized i.m.
and intranasally (i.n.) at days 0 and 29, respectively. Each
animal received 2 ml of a preparation containing a pseudovirion
titer between 105.625 and 106.125 IU/ml. Five mock-inoculated
animals were used as controls in each experiment. All animals
were tested for clinical signs, virus shedding, and viremia fol-
lowing immunization and challenge infection. Intranasal chal-
lenge infection was performed 28 days after the last immuniza-
tion using 2 ml of a preparation with a titer of 106 TCID50/ml of
the virulent, heterologous BVDV strain SE5508.
After immunization and challenge infection, virus isolation
was performed in duplicates on KOP-R cells with blood sam-
ples and nasal swabs using co-cultivation of 1×106 blood
leukocytes or 100 μl of nasal swab supernatants. After an
incubation period of 4 to 5 days, the cells were analyzed for NS3
expression by IF.
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